Introduction {#Sec1}
============

Although advances in screening and treatment have substantially improved survival from colorectal cancer (CRC), clinical outcomes vary widely among patients with tumors diagnosed at the same TNM stage, and disease relapse occurs in 20--30% of patients with localized cancer^[@CR1]^. The presence of microsatellite instability (MSI-H) in colorectal cancers have a better prognosis as compared to microsatellite stable (MSS) colorectal cancer^[@CR2]--[@CR5]^. The mechanisms that confer this benefit are not fully understood, but an association has been linked to the prominent infiltration of immune cells within the tumor^[@CR6]^. Increased focus on the tumor microenvironment has identified inflammatory activity as a critical predictor of disease activity impacting patient prognosis.

The host immune response has been implicated in tumor behavior as it influences all phases of tumor development and growth^[@CR7]--[@CR9]^. Tumor-infiltrating lymphocytes (TILs) in histopathological analysis of CRC is often interpreted as the host protecting against tumor development^[@CR10],[@CR11]^. TILs mediate recruitment, maturation, and activation of immune cells that suppress tumor growth. Tumor infiltration by T lymphocytes is a highly informative prognostic factor for CRC outcome, independent of traditional prognostic indicators^[@CR12]--[@CR14]^. Numerous studies have demonstrated that the type, density and site of tumor-infiltrating lymphocytes in primary tumors are prognostic for disease-free survival (DFS) and overall survival (OS) from CRC and hints at a fundamental function of the immune system in the tumor microenvironment^[@CR15]--[@CR18]^.

However, variability in study design, outcomes, sample size, and methods of measuring the host immune response reflecting the heterogeneity of studies in the literature inspired this systematic analysis. Recently, large retrospective studies have reported their data on the prognostic performance of TIL in CRC survival. To obtain a more precise estimate of the effect in populations with CRC, we performed an updated systematic review and meta-analysis to measure the impact of TILs on CRC survival.

Methods {#Sec2}
=======

Protocol and registration {#Sec3}
-------------------------

We developed a protocol based on standard guidelines for the systematic review of prognostic studies and followed suggestions on updating systematic reviews as outlined by Moher *et al*.^[@CR19]^. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements for reporting our systematic review^[@CR20]^. Methods of the analysis and inclusion criteria were specified *a priori* in a protocol.

Data sources and search strategy {#Sec4}
--------------------------------

A librarian (LK) developed searches using a combination of keywords and controlled vocabulary (when available) in the following databases: PubMed (Appendix 1), Embase (Appendix 2 & 3), initially through OvidSP and later via Elsevier, Cochrane Library (Appendix 4), Web of Science (Appendix 5), and ClinicalTrials.gov (1997 to April 2017). In addition, we search grey literature sources (https//www.usa.gov, https://scholar.google.com) to identify relevant publications. The English language filter was used when available. We also examined bibliographies of related papers and reviews, while also consulting with experts in the field. In addition, we evaluated reference lists of previously published systematic reviews and meta-analysis.

Eligibility criteria {#Sec5}
--------------------

All studies were reviewed initially based on title and abstract. If the data was insufficient based on title and abstract, the full text article would be reviewed. Two independent reviewers (GEI and NB) reviewed the first 100 results of the Ovid Medline search to assess for agreement of article selection with a kappa of 0.82. Then further search results were divided equally amongst GI and NB. Disagreement was resolved either by discussion, consensus or by a third party (SBG).

For study inclusion, the keywords included focused on generalized tumor inflammatory infiltrate and associated T lymphocytes' subsets (CD4, CD8) in colorectal cancer patients identified with hematoxylin and eosin stain (HE) or immunohistochemical staining (IHC) and reported prognostic information. IHC staining was evaluated in subgroup analysis for tumor center (CC) and tumor stroma (TS) and at the invasive tumor margin (IM). Prognostic information included overall survival (OS) and disease-free survival (DFS).

Exclusion criteria included those publications for which there was insufficient data to estimate a hazard ratio (HR) with a 95% confidence interval (CI). However, references from review articles, case reports, commentaries and letter were reviewed to identify any additional studies that met the inclusion criteria. An effort was made to contact the authors for any clarifications.

Data extraction and quality assessment {#Sec6}
--------------------------------------

Two reviewers (GEI, JK) independently evaluated and extracted relevant information from each included study. We utilized a form originally developed from the work of McShane *et al*.^[@CR21]^ and Hayes *et al*.^[@CR22]^ adapted by Mei *et al*.^[@CR18]^ for quality assessment in their systematic review and meta-analysis as this adaptation was comprehensive (See Supplement [1](#MOESM1){ref-type="media"}). It resulted in a quality rating of 0--9 based on reporting of inclusion and exclusion criteria, study design (prospective or retrospective), patient and tumor characteristics, description of the method or assay, study endpoints, follow-up time with patients and number of patients that dropped out during the follow-up period^[@CR18]^.

Data collection process {#Sec7}
-----------------------

A standardized data abstraction form was adapted from Mei *et al*. to include key elements pertaining to the study design, sample size, patient age, stage of disease, assay method, follow-up duration, and HR estimates (with the corresponding 95% CIs) for TILs at certain locations within tumors (CT, TS or IM) and the HR cutoff point, method of quantifying (immunohistochemistry, PCR, sequencing). For time-to-event outcomes, we retrieved and curated the HR estimates with 95% CI from the original articles^[@CR18]^. Discrepancies in interpretation between reviewers (GEI, NB) were resolved by discussion with a third reviewer (SBG) to reach consensus.

Subgroup analyses {#Sec8}
-----------------

We performed analyses to estimate the association between prognostic outcomes (OS, CS, DFS) and both T-lymphocyte subsets (CD3 + , CD8 + , FOXP3 + , CD45R0 + ) and T lymphocyte infiltrate location (CC, TS, or IM). Survival time was recorded from either the date of diagnosis or the initiation of treatment, as available from the published reports. Random effects models were used consistent with prior published meta-analyses that showed evidence of heterogeneity for similar subgroup analyses.

Summary measures {#Sec9}
----------------

Meta-analyses were performed using the R package 'meta' version 4.9-0, using statistical software R (version 3.4.3). Random effects models were calculated based on HR estimates and their standard errors; inverse weighting was used for pooled variance. We then plotted forest and funnel charts by T-cell type, T-cell source and outcome to evaluate for publication bias. Interstudy heterogeneity was quantified using the *I*^2^ statistic, with an *I*^2^ value\>50% as our *a priori* threshold for substantial heterogeneity^[@CR23]^.

Results {#Sec10}
=======

Literature search {#Sec11}
-----------------

Eligible studies were identified and selected as shown in Fig. [1](#Fig1){ref-type="fig"}. Among the 3,789 studies identified for initial evaluation, 1,963 studies were eligible for further assessment based on pre-specified criteria. Abstracts of these studies were reviewed and 1,804 studies were excluded for the reasons delineated in Fig. [1](#Fig1){ref-type="fig"}. After abstract review, we identified 159 articles for full manuscript review and 106 of these studies were excluded. The most common reasons for exclusion were studies were the following: No relevant outcome (N = 63); Shared identical population (N = 23); and Editorial, letter, or commentary (N = 19). There were 53 studies eligible for inclusion, but 10 studies were found to have insufficient data. Therefore, 43 studies were included in the final meta-analysis (Table [1](#Tab1){ref-type="table"})^[@CR24]--[@CR65]^.Figure 1TIL Meta-Analysis Flow Diagram.Table 1Summary of study subsets and variables included in analysis.YearFirst AuthorCounting SiteT-cell SubsetOutcomesAssayVariables1997RopponenGeneralTILOSHEAge, sex, site, surgical treatment, post-op complications, histology1998NaitoIMCD8OSIHCPattern on invasion, histological type1999NielsenGeneralTILOSIHCGrade, site2001GuidoboniCCCD3, CD8, GRBDFS, OSIHCAge, sex, pathologic stage, grade, histology, ploidy, adjuvant chemo, life status, recurrence2001NagtegaalGeneralCD3, CD4, CD8OSIHC/HEN/A2001ParafCCCD3OSIHCAge, tumor size, expanding margin, CLR, tumor site, differentiation, pTNM stage, vascular and perineural invasion, peripheral adenomatous residue2002CianchiGeneralTILOSHistopathAge, sex, histotype, tumor differentiation, depth of invasion, venous invasion, character of invasive margin, conspicuous lymphocytic infiltration, tumor relapse2004ChibaCCCD8CSSIHCKi67, site, invasion pattern, differentiation2004MenonIMCD45DFSIHC/HEAge, sex, location, stage, differentiation, mucinous, BM-like, recurrence2004PrallCCCD8CSS, OSIHC/HELocation, substage, adjuvant therapy, MSI2005BuckowitzGeneralTILOSHEAge, clinical criteria, treatment, localization, stage, T, N, M, Crohn's like reaction, survival2005GaoGeneralTILOSHEGender, age, tumor location, Duke's stage, growth pattern, differentiation, DNA ploidy, S-phase fraction, p53 expression2005KlintrupGeneralTILOSHEDuke's stage, WHO grade, tumor location2006GalonCCCD3 CT/IM patternOSIHCTNM, differentiation2009OginoGeneralTILCSS, OSIHCBMI, lymph node count, KRAS, BRAF, p53, PTGS2, MSI, CIMP, LINE-1 methylation2009RoxburghGeneralCD3OSIHC/HEki67, pi16, tumor differentiation, serosal involvement, margin involvement, tumor perforation, venous invasion, mGPS2009SalamaCCFOXP3CSSIHCStage, tumor site, histologic grade, vascular invasion, lymphatic invasion, perineural invasion, lymphocytic response, MSI2009SinicropeTSFoxP3OS, DFSIHCHistologic grade, tumor site, chemo2010CorrealeTSCD8 CCR7+OSIHC/HEPerformance status, sex, age, tumor grade, liver mets2010DeschoolmeesterCCCD3, CD8, GRBOS, DFSIHCLocation, grade, neo-adjuvant, adjuvant, MSI2010FreyCCCD3, CD8, FOXP3CSSIHC/HEAge, tumor diameter, tumor location, grade, histology, vascular invasion, tumor border configuration2010LeeTSCD3, CD45RO, FOXP3OSIHCCEA, size, lymphatic invasion, vascular invasion, perineural invasion2010NoshoCCCD3, CD8, CD45RO, FOXP3OS, CSSIHCBMI, family history, tumor location, tumor grade, KRAS, BRAF, PIK3CA, MSI, CIMP, LINE-1 hypomethylation2010PengGeneralCD3, CD45ROOSIHCTumor site, pathologic grade2010SimpsonCCCD3CSSIHCSex, grade, vascular invasion, site, MHC class I, MSI2011DahlinGeneralCD3 (MLH1, MSH2, MSH6, PMS2)CSSIHCMSI2012HuhGeneralTILOS, DFSHE?Age, tumor size, differentiation, lymphovascular invasion, perineural invasion, preoperative CEA, macroscopic ulceration, tumor border configuration2012RichardsGeneralCD3, CD8, CD45RO, FOXP3CSSHE stainAge, sex, elective/emergency, tumor site, anemia, WBC, SIR(S), K-M, T, N, TNM, Peterson Index2012YoonCCCD8OSIHCGrade, site2013KimCCFoxP3OSIHCAge, gender, level of wall infiltration, lymph node metastasis2013LewisGeneralCLR (Crohns like reaction)OS, PFSHELack of dirty necrosis, mucin differentiation, signet ring cell feature, medullary feature, histological heterogeneity, background dysplasia, 5-FU based chemo2014Di CaroIMCD3DFSIHCN/A2014LingTSCD8, FOXP3CSSIHCMSI, CIMP2014ReimersCCFoxp3OS, DFSTMA, IHCAge, gender, tumor grade, adjuvant therapy, circumferential margin2014RichardsIMCD3, CD8, CD45RO, FOXP3CSSIHCPreoperative systemic inflammatory response, Carstairs Deprivation Index, ASA grade, smoking status, POSSUM physiology scores, tumor differentiation, venous invasion, tumor necrosis, adjuvant chemo2015KimIMCD8, CD45RO, FOXP3OSIHC, TMAAge, gender, pTNM, lymphatic invasion, distant metastasis, MSI, CIMP, KRAS, BRAF, tumor location, adjuvant chemotherapy2015MoriCCCD8DFSIHCNLR, PLR, CRP, MSI2015ReissfelderCCCD4, CD8, FOXP3OSIHCGender, UICC, TNM, operative procedure2015VladIMCD3OSIHCAge, tumor location, TNM stage, histological grade, vascular, lymphatic and perineural invasion2015WangCCFOXP3OSIHCAge, gender, tumor size, differentiation, mucinous type, LN mets, T4, post-op chemo, tumor location, albumin2016RozekGeneralTIL, CLROS, CSSHECLR, grade, MSI2016SinicropeGeneralFoxP3DFS, OSIHCHistologic grade, tumor site, chemo2016ChenCCCD3, CD4, CD8, CD45R0,DFS, OSIHCAge, gender, tumor site, TNM stage, LNR, VELIPI, tumor diameter, resection margin, differentiation, histopathology

Study characteristics {#Sec12}
---------------------

Characteristics for each study are summarized in Table [1](#Tab1){ref-type="table"}. Forty-three studies had a median quality score of 6 out of 9 (range: 3--8) and consisted of a median of 243 patients (range: 42--2,369), with a median follow-up of 64 months (range: 18--240). All studies were published from 1997--2017. There was one study included from an abstract due to the large number of patients (N = 2,293) included in the retrospective study (Sinicrope *et al*.^[@CR64]^). Study sample sizes range from 42 to 2,396 patients representing an overall total of 21,015 patients. HRs and 95% CI for overall survival (OS), cancer-specific survival (CSS), or disease-free survival (DFS) were derived directly when available. A synopsis of study variables and results are summarized in Table [1](#Tab1){ref-type="table"} and Table [2](#Tab2){ref-type="table"}, respectively.Table 2Summary of study outcome measures by subset.LocationOverall SurvivalCancer-Specific SurvivalDisease-Free SurvivalTILGeneral12 studies4 studies3 studiesHR: 0.6595% CI: 0.54--0.77HR: 0.5895% CI:0.46--0.73HR: 0.7295% CI:0.60--0.88CD3Total Studies11 studies4 studies7 studiesTumor CenterHR: 0.6795% CI:0.45--1.00HR: 0.7995% CI:0.57--1.11HR: 0.4695% CI:0.36--0.61Invasive MarginHR: 0.6995% CI:048--1.00HR: 0.4995% CI:0.38--0.63HR: 0.5795% CI:0.38--0.86StromaHR: 0.8995% CI:0.49--1.61HR: 0.5895% CI:0.45--0.75HR: 0.7095% CI:0.27--1.81CD4Total Studies2 studies1 studyTumor CenterHR: 0.8395% CI:0.53--1.30HR: 0.5595% CI:0.31--0.97CD8Total Studies9 studies5 studies5 studiesTumor CenterHR: 0.7195% CI: 0.53--0.94HR: 0.6595% CI:0.52--0.80HR: 0.7195% CI:0.53--0.94Invasive MarginHR: 0.8795% CI:0.71--1.07HR: 0.6195% CI:0.37--1.01StromaHR: 0.7395% CI:0.56--0.97HR: 0.7195% CI:0.55--0.92HR: 1.9595% CI:0.66--5.76CD45R0Total Studies5 studies1 studies2 studiesTumor CenterHR: 0.5995% CI:0.45--0.78HR: 0.1395% CI:0.02--1.18HR: 0.5195% CI:0.33--0.80Invasive MarginHR: 0.4795% CI:0.33--0.66StromaHR: 0.1395% CI:0.02--1.16HR: 0.2095% CI:0.06--0.71FoxP3Total Studies11 studies4 studies4 studiesTumor CenterHR: 0.7095% CI:0.57--0.87HR: 0.6695% CI:0.55-0.79HR: 0.7595% CI:0.39--1.46Invasive MarginHR: 0.6595% CI:0.49--0.88HR: 0.7395% CI:0.56--0.96StromaHR: 0.5295% CI:0.27--0.99HR: 0.4895% CI:0.21--1.06GeneralHR:0.5395% CI:0.24--1.18HR: 0.6595% CI:0.54--0.78

Subgroup analysis {#Sec13}
-----------------

Prognostic effect estimates were pooled for generalized tumor inflammatory infiltrate counts and T-lymphocyte subsets stratified by tumor location (IM, TS, CC) in CRC. Due to limited numbers and low sample sizes of studies within each subset, estimates of between-study heterogeneity were imprecise. Therefore, we performed funnel plot analyses for both generalized tumor inflammatory infiltrates and T-cell subsets.

Generalized tumor infiltrating lymphocytes {#Sec14}
------------------------------------------

Density of generalized tumor infiltrates within CRC were pooled from fourteen studies for analysis (Fig. [2](#Fig2){ref-type="fig"}). All studies indicate improved prognosis for the presence of TILs for OS (HR = 0.65; 95% CI, 0.58--0.77), CSS (HR = 0.58; 95% CI, 0.46--0.73), and DFS (HR = 0.72; 95% CI, 0.60--0.88). There was no indication of publication bias for OS based on funnel plot analysis. However, moderate heterogeneity was noted in the OS subgroup (*I*^2^ = 54%, *P* = 0.02).Figure 2Forest plots of random effects between levels of generalized inflammatory infiltrate and survival. (**A**) The effect of generalized tumor infiltrate on cancer-specific survival (CSS), disease-free survival (DFS), and overall survival (OS). (**B**) Funnel plots of meta-analyses to assess the association between TILs and survival.

CD3+ T lymphocyte subset {#Sec15}
------------------------

The CD3 antigen is a T-cell co-receptor glycoprotein that plays an essential role in adaptive immune response. The association between the presence of CD3+ T lymphocytes and survival of CRC patients was extracted from fourteen studies (Fig. [3](#Fig3){ref-type="fig"}) stratified by tumor location, with eleven evaluating the tumor center, four the tumor stroma, and five the IM. The pooled HRs from the tumor center were calculated for OS (HR = 0.67; 95% CI, 0.45--1.00), CSS (HR = 0.79; 95% CI, 0.57--1.11), and DFS (HR = 0.46; 95% CI, 0.36--0.61). Statistically significant heterogeneity was observed between studies in the OS group (*I*^2^ = 86%, P \< 0.01). The pooled HRs from the tumor margin (IM) were calculated for OS (HR = 0.69; 95% CI, 0.48--1.00), CSS (HR = 0.49; 95% CI, 0.38--0.63), and DFS (HR = 0.57; 95% CI, 0.38--0.86). The pooled HRs from the tumor stroma (TS) were calculated for OS (HR = 0.89; 95% CI, 0.49--1.61), CSS (HR = 0.58; 95% CI, 0.45--0.75), and DFS (HR = 0.70; 95% CI, 0.27--1.81).Figure 3Forest plots of random effects between levels of CD3+ T-cell infiltrate and Survival. The effect of CD3+ T-cells in the (**A**) tumor center (**B**) invasive margin (**C**) stroma on cancer-specific survival (CSS), disease-free survival (DFS), and overall survival (OS).

CD8+ T lymphocyte subset {#Sec16}
------------------------

CD8+ T cells are cytotoxic T cells that promote apoptosis of cancer cells^[@CR66]^. The association between the presence of CD8+ T lymphocytes and survival of CRC patients was extracted from thirteen studies (Fig. [4](#Fig4){ref-type="fig"}) stratified by tumor location, with twelve evaluating the tumor center, five the stroma, and five the invasive margin. The pooled HRs from the tumor center were calculated for OS (HR = 0.71; 95% CI, 0.53--0.94), CSS (HR = 0.65; 95% CI, 0.52--0.80), and DFS (HR = 0.32; 95% CI, 0.18--0.56). Statistically significant heterogeneity was observed between studies for OS (*I*^2^ = 86%, P \< 0.01). The pooled HRs from the IM were calculated for OS (HR = 0.92; 95% CI, 0.82--1.03) and DFS (HR = 0.61; 95% CI, 0.37--1.01). The pooled HRs from the TS were calculated for OS (HR = 0.73; 95% CI, 0.56--0.97) CSS (HR = 0.71; 95% CI, 0.55--0.92) and DFS (HR = 1.95; 95% CI, 0.66--5.76). Estimated HRs for CSS and DFS for CD8 + lymphocyte infiltrates from the tumor stroma were provided from a single study.Figure 4Forest plots of random effects between levels of CD8+ T-cell infiltrate and Survival. The effect of CD8+ T-cells in the (**A**) tumor center (**B**) invasive margin (**C**) stroma on cancer-specific survival (CSS), disease-free survival (DFS), and overall survival (OS).

FOXP3+ Treg subset {#Sec17}
------------------

FOXP3+ Tregs suppress aberrant immune response against self-antigens and maintain homeostasis of the immune system^[@CR67]^. The association between the presence of FOXP3+ T lymphocytes and survival of CRC patients was extracted from fourteen studies (Fig. [5](#Fig5){ref-type="fig"}) stratified by tumor location, with eleven evaluating the CC, four the TS, and three the IM. The pooled HRs from the tumor center were calculated for OS (HR = 0.70; 95% CI, 0.57--0.87), CSS (HR = 0.66; 95% CI, 0.55--0.79) and DFS (HR = 0.75; 95% CI, 0.39--1.46). The pooled HRs from the IM were calculated for OS (HR = 0.65; 95% CI, 0.49--0.88) and CSS (HR = 0.73; 95% CI, 0.56--0.96). The pooled HRs from the TS were calculated for OS (HR = 0.52; 95% CI, 0.27--0.99) and DFS (HR = 0.48; 95% CI, 0.21--1.06).Figure 5Forest plots of random effects between levels of FOXP3+ T-cell infiltrate and Survival. The effect of FOXP3+ T-cells in the (**A**) tumor center (**B**) invasive margin (**C**) stroma on cancer-specific survival (CSS), disease-free survival (DFS), and overall survival (OS).

CD45R0+ Treg subset {#Sec18}
-------------------

The association between the presence of CD45R0+ T lymphocytes and survival of CRC patients was extracted from four studies (Fig. [6](#Fig6){ref-type="fig"}) stratified by tumor location, with three assessing the CC, one the TS, and one the IM. The pooled HR from the tumor center panel were calculated for OS (HR = 0.59; 95% CI, 0.45--0.78), CSS (HR = 0.51; 95% CI, 0.33--0.80) and DFS (HR = 0.13; 95% CI, 0.02--1.18). Estimated HRs for OS and DFS for CD45R0 + lymphocyte infiltrates from the invasive margin and tumor stroma were provided from single studies.Figure 6Forest plots of random effects between levels of CD45R0+ T-cell infiltrate and Survival. The effect of CD45R0+ T-cells in the (**A**) tumor center (**B**) invasive margin (**C**) stroma on cancer-specific survival (CSS), disease-free survival (DFS), and overall survival (OS).

Discussion {#Sec19}
==========

We have performed a systematic review and quantitative meta-analysis of the prognostic impact of tumor infiltrating lymphocyte density and composition on CRC outcome. Through a computerized, systematic literature search of Medline, Embase, Web of Science, and Scopus databases using pre-determined inclusion criteria, we identified 43 studies published between August 1997 and April 2017 (representing a total of 21,015 CRC patients with available samples) that evaluate specific marker subset populations of tumor infiltrating lymphocytes in CRC and survival outcomes. We separately considered Generalized TIL density, CD3, CD8, FOXP3, CD45R0 as the focus of our meta-analysis, recognizing that there are other systems of scoring the host immune response that are beyond the scope of the current meta-analysis. Since the publication of an initial meta-analysis of TILs and CRC in 2014 by Mei *et al*. which included 7840 patients, there have been an additional 13,175 CRC patients with tissue samples that have undergone analysis for TIL density by T-cell subset and histopathologic location. Due to the increasing recognition of intratumoral adaptive immune reaction as a prognostic marker for survival and as a therapeutic target of immune checkpoint inhibitors, we performed an updated systematic review and meta-analysis of TIL.

Pooled analysis from an extensive compilation of studies suggest that high generalized TIL counts and CD3+ T-cell density have the strongest association with survival benefit for patients as compared to low generalized TIL counts and CD3+ T-cell density in regards to disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS). The pooled summary HRs for each T-cell subset were inconsistent across different studies. Some markers trended towards a stronger prognostic association with survival as compared to the earlier analysis performed by Mei *et al*. (CD3, CD8, FOXP3).

The effect of the immune system in colorectal cancer is still being elucidated as several prospective and retrospective studies demonstrate that robust antitumor immunity is associated with favorable prognosis in patients with CRC. Notably, we confirmed in our study a prognostic benefit of FoxP3+ T cell infiltrates which stands in contrast to previous meta-analyses suggesting that tumor-infiltrating FoxP3+ T-cells are associated with poor clinical outcomes in solid cancers^[@CR68],[@CR69]^. Recent studies elucidating the interplay between the tumor microenvironment and colonic microbiome have identified two distinct subpopulations of immunosuppressive and proinflammatory FOXP3+ T-cells. Investigators found that proinflammatory FoxP3^lo^ T-cells were associated with an increased presence of *Fusobacterium nucleatum* and better CRC patient prognosis, while immunosuppressive FOXP3+ T-cellls were associated with worse outcomes^[@CR70]^. Additional TIL research is ongoing in understanding the modulation of T-cell trafficking by the gut microbiome and the control of tumor growth through direct lysis of cancer cells through the production of cytokines that promote a cytotoxic response^[@CR71],[@CR72]^. In addition, new immunotherapies are being developed that harness adoptive transfer of marker-specific TIL populations to elicit an immune response to tumors^[@CR73]^.

Our meta-analysis demonstrates that generalized TIL density is a strong prognostic marker for survival in patients with colorectal cancer. This result is concordant with previous studies that identified the association of TILs with increased survival^[@CR74]^. The strengths of the study include the addition of large retrospective studies by Rozek *et al*.^[@CR63]^, and Sinicrope *et al*.^[@CR64]^, which included 2,369 patients and 2,293 patients respectively, adding further precision and generalizability to the recognition that TILs confer a prognostic advantage with a maximum likelihood HR = 0.65 for overall survival.

These findings are consistent with previous meta-analyses^[@CR18]^, yet our results have caveats that are relevant to this type of summary analysis. Heterogeneity existed in most analyses even though subgroup and overall summary estimates were similar. Also, studies that utilize different methods of TIL identification, small populations, and variations associated with archival specimens were pooled. Nonetheless, the more homogeneous TIL density summary estimates were similar to the overall summary estimates, suggesting that the overall summary measures are a reasonable estimation of prognosis associated with TILs. Second, the meta-analysis was subject to detection, verification and spectrum biases from the original studies. We may have overlooked relevant studies with results (negative or limited) that would modify the estimates. In addition, the different cutoff values for designation of high vs low TIL was a source of bias for this meta-analysis. Among the analyzed studies, the cutoff values included presence or absence (Nagtegaal *et al*.^[@CR28]^; Cianchi *et al*.^[@CR30]^; Gao *et al*.^[@CR32]^; Ogino *et al*.^[@CR37]^; Richards *et al*.^[@CR50],[@CR57]^), TIL count with a different threshold for high vs low (Lee *et al*.^[@CR44]^; Rozek *et al*.^[@CR63]^), and mean, media, and quartiles (Naito et al.^[@CR25]^; Guidoboni *et al*.^[@CR27]^; Chiba *et al*.^[@CR31]^; Menon *et al*.^[@CR33]^; Galon *et al*.^[@CR14]^; Salama *et al*.^[@CR39]^; Frey *et al*.^[@CR43]^; Lee *et al*.^[@CR44]^; Nosho *et al*.^[@CR45]^; Sinicrope *et al*.^[@CR40],[@CR64]^; Yoon *et al*.^[@CR51]^; Di Caro *et al*.^[@CR54]^). Some studies detected TILs by tissue microarray while others used full histologic sections. These differences could be responsible for the variability in reaching a standardized method of TIL evaluation. Galon *et al*. along with other groups including Robins *et al*.^[@CR75]^ are making efforts to develop standardized methods to evaluate TILS in order to improve consistency and reproducibility of TIL measurements for future diagnostic studies, yet these techniques have not been broadly adapted enough to summarize with meta-analysis of these specific approaches^[@CR76]^. Given our results and the extensive literature demonstrating the intratumoral immune cell infiltrate as a highly informative prognostic indicator, further studies are warranted towards the goal of optimizing tumor classification and cancer staging.
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